External Nasal Dilator - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The external nasal dilator market size is expected to increase from USD 333.33 million in 2025 to USD 354.03 million in 2026 and reach USD 478.49 million by 2031, growing at a CAGR of 6.21% over 2026-2031. This report is segmented by Application (Snoring, Sleep Apnea Support, Nasal Congestion, Exercise and Sports Breathing, and Other Applications), End User (Adults and Pediatric), Distribution Channel (Offline and Online), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global External Nasal Dilator Market Trends and Insights

Rising Prevalence of Snoring, Nasal Congestion, and Sleep-Disordered Breathing

An estimated 936 million adults aged 30 to 69 had mild-to-severe obstructive sleep apnea globally, and prevalence had risen 12% from the prior decade. A 2025 literature-based review estimated that 83.7 million U.S. adults lived with obstructive sleep apnea in 2024, representing a modeled adult prevalence of 32.4%. The external nasal dilator market addresses the nasal-origin snoring and congestion component of this burden, rather than the anatomical causes of apnea. Urbanization, obesity, physical inactivity, and air quality pressures can also increase allergic rhinitis and chronic nasal symptoms. These factors extend demand beyond sleep use and into daily congestion management. Annual workplace productivity losses related to obstructive sleep apnea were estimated at USD 180.2 billion in the United States and GBP 4.22 billion, or USD 5.5 billion, in the United Kingdom.

Growing Preference for Drug-Free, Non-Invasive Airflow Relief

Many consumers prefer mechanical airflow relief because it does not involve systemic absorption, drug interactions, or rebound congestion. This preference is especially relevant for people who avoid decongestants because of potential side effects or repeated use concerns. The external nasal dilator market can therefore serve a broad group of consumers seeking a non-drug option. A 2026 study of well-trained endurance athletes found that nasal decongestion lowered mean capillary blood lactate after an exhaustion test and improved ventilatory efficiency during submaximal exercise stages. The results support interest in nasal patency, although they do not establish that every nasal strip improves peak athletic performance. The distinction between device registration and a cleared therapeutic claim makes peer-reviewed evidence important for brands that seek stronger, compliant positioning.

Limited Efficacy for Non-Nasal Causes of Obstructive Sleep Apnea

Nasal dilators can improve airflow and lower nasal resistance, but they do not resolve apnea caused by tongue-base collapse or other oropharyngeal anatomy. A 2024 clinical policy review reported that 12 of 14 reviewed studies found no significant change in the apnea-hypopnea index with nasal dilators. This limitation keeps the external nasal dilator market focused on nasal-origin snoring, congestion, and selected wellness needs. Consumers whose snoring persists may stop repurchasing after they recognize that the underlying cause is outside the product's scope. Broad snoring claims can therefore lead to returns and unfavorable online reviews when brands do not explain the appropriate use case. Stronger clinical differentiation is difficult when lower-priced products make similar broad claims without meaningful evidence.

Other drivers and restraints analyzed in the detailed report include:

• Rising Adoption for Exercise and Sports Breathing
• Expansion of Direct-to-Consumer Availability and Product Innovation
• Skin Irritation, Fit Variability, and Claim Requirements

Segment Analysis

Snoring commanded 48.5% of revenue in 2025, while exercise and sports breathing is projected to expand at an 8.5% CAGR through 2031. Snoring remains the largest application because adhesive strips have deep consumer recognition as a simple response to nighttime breathing concerns. The segment benefits from buyers who identify nasal congestion as a contributor to snoring and want a drug-free option. Sleep apnea support and nasal congestion form the next major application groups after snoring. These use cases often overlap because people who buy for nighttime congestion can also recognize an effect on nasal-origin snoring. This overlap supports trial across more than 1 use occasion. The external nasal dilator market has a clear boundary in this segment because the product does not treat apnea caused by non-nasal anatomy. Brands must communicate that boundary clearly to avoid consumer expectations that cannot be met.

Exercise and sports breathing is growing as nasal strips become more visible during training and recovery. The 2025 nasal-breathing study found faster post-exercise muscle oxygenation recovery with nasal breathing, which supports recovery-oriented communication. Rhinomed separates its sport-focused Turbine product from its sleep-focused mute dilator through sporting goods distribution. This approach recognizes that athletic users and sleep users can respond to different product messages and buying locations. Other applications include post-surgical nasal support, travel use, and seasonal allergy management. These episodic uses increase the number of potential occasions for product trial. Sports-oriented products also face a higher evidence standard because performance claims can be contested. The segment is better supported when brands focus on nasal patency, comfort, and recovery rather than making broad promises about athletic results.

Complete Report Scope:

• By Application
  • Snoring
  • Sleep Apnea Support
  • Nasal Congestion
  • Exercise and Sports Breathing
  • Other External Nasal Dilator Applications
• By End User
  • Adults
  • Pediatric
• By Distribution Channel
  • Offline
  • Online
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.4% of external nasal dilator market revenue in 2025, making it the largest regional base. The United States accounts for most regional demand because of its sleep-health burden, established OTC retail network, and active product development environment. An estimated 83.7 million U.S. adults were living with obstructive sleep apnea in 2024, while related workplace productivity losses were estimated at USD 180.2 billion annually. Prestige Consumer Healthcare completed its acquisition of Breathe Right for USD 1.045 billion in June 2026, reinforcing the strategic importance of the U.S. nasal strip category. Canada and Mexico add to the regional base, while the United States remains central to patents, launches, and clinical activity.

Europe is the second-largest region in the external nasal dilator market, with Germany, the United Kingdom, and France as its strongest national markets. Germany benefits from a developed pharmacy network, while the United Kingdom has established branded-product advocacy in digital retail and France has a more physician-influenced purchase pattern. Sports events have also increased consumer visibility in France, although clinical evidence behind some airflow claims remains contested. Italy and Spain are growing secondary markets, and Scandinavia and the Benelux region add meaningful volume to the Rest of Europe. The region's pharmacy culture helps physical retail remain important as e-commerce expands.

Asia-Pacific is projected to grow at a 7.4% CAGR through 2031, the fastest rate among geographic segments. China, India, and Japan offer large potential consumer bases as urban awareness and e-commerce access expand, while South Korea's athletic culture supports sports-breathing demand. In Australia, pharmacy-led consumer health retail remains important for brands distributed through Chemist Warehouse and Priceline. Middle East and Africa and South America have smaller shares, but rising urban sleep-health awareness and consumer wellness spending support their development.

List of Companies Covered in this Report:

• AdvaCare
• AirWare Labs Corp.
• ASO LLC
• Creganna
• CNS, Inc.
• Corbett Lair Inc.
• GlaxoSmithKline
• Foundation Consumer Healthcare LLC
• M&M Pure Air Systems LLC
• McKeon Products, Inc.
• Nasanita
• Nasal Aid
• Perrigo Company
• Scandinavian Formulas
• SANOSTEC CORP
• Splintek, Inc.
• The Sleep Better Company
• Tomed GmbH
• Victoreks Health Products Ltd.
• WoodyKnows
• Rhinomed Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support